​

Tysabri and Progressive Multifocal Leukoencephalopathy: Legal Considerations in Texas

From General Health Information to Targeted Risk Awareness

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical treatments and their associated risks. This legacy context provided broad awareness of therapeutic options, including biologic medications used in chronic disease management. Within this framework, patients and healthcare professionals alike have navigated the balance between treatment benefits and potential adverse effects, relying on established channels for safety communication. As this informational landscape evolved, a more focused concern emerged regarding specific pharmaceutical exposures and their long-term implications. One such area involves the medication Tysabri, prescribed for certain autoimmune conditions, and its recognized association with Progressive Multifocal Leukoencephalopathy (PML)—a serious brain infection. This shift from general health awareness to targeted risk assessment has become particularly relevant in occupational and legal settings, where individuals may have been exposed to the drug through their work environment, such as in healthcare administration, pharmaceutical manufacturing, or clinical trial oversight. The transition from broad health literacy to occupational exposure concern necessitates careful consideration of timelines and legal frameworks. In Texas, the statute of limitations for claims related to Tysabri and PML exposure imposes strict deadlines for seeking legal recourse. This pivot underscores the need for specialized knowledge that moves beyond general health information into the nuanced intersection of pharmaceutical risk, workplace safety, and legal accountability.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn disease. Its prescribing information contains a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, and three factors are known to increase the risk in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These risk factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can include progressive neurological deficits such as cognitive impairment, motor weakness, gait disturbance, and visual changes. In the FDA Adverse Event Reporting System (FAERS), the most frequently reported adverse events associated with Tysabri include fatigue, multiple sclerosis relapse, headache, gait disturbance, balance disorder, memory impairment, and cognitive disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These symptoms overlap with those of PML, making early diagnosis challenging. Healthcare professionals are instructed to monitor patients on Tysabri for any new sign or symptom suggestive of PML and to withhold Tysabri dosing immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

​

Mechanism of PML and Risk Factors

The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist, which inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect can reactivate latent JCV in the brain, leading to lytic infection of oligodendrocytes and subsequent demyelination. The latency period between Tysabri exposure and PML onset can vary, but risk increases with cumulative treatment duration, particularly beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For patients who develop PML, the prognosis is poor, with most cases resulting in severe disability or death. From a legal perspective, patients in Texas who have developed PML after Tysabri treatment may have claims related to inadequate warnings. The boxed warning and prescribing information clearly state the risk of PML and the need for monitoring, but questions may arise about whether these warnings were sufficient to inform patients and healthcare providers of the full scope of risk, especially given the drug's availability only through the TOUCH program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The adequacy of warnings is a central issue in product liability litigation, as plaintiffs must demonstrate that the manufacturer failed to provide adequate information about the risks, and that this failure caused harm.

Statute of Limitations for Tysabri Claims in Texas

The statute of limitations for personal injury claims in Texas is generally two years from the date the injury is discovered or should have been discovered with reasonable diligence. For PML, the timeline between Tysabri exposure and documented harm can be prolonged, and symptoms may initially be attributed to multiple sclerosis relapse rather than PML. This can complicate the determination of when the statute of limitations begins to run. Patients who have been diagnosed with PML after Tysabri treatment should consult with an attorney experienced in pharmaceutical litigation to assess their individual circumstances, including the date of diagnosis, the duration of Tysabri therapy, and any prior immunosuppressant use. The TOUCH program requires regular evaluations and reporting of PML cases to Biogen (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), which may provide documentation relevant to the timeline of exposure and harm. In summary, Tysabri carries a well-documented risk of PML, with specific risk factors including anti-JCV antibody status, treatment duration, and prior immunosuppressant use. Patients in Texas who have developed PML should be aware of the potential for legal claims based on inadequate warnings and should act promptly to preserve their rights within the applicable statute of limitations. Medical monitoring and early intervention are critical, as PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Time is limited. Request your evaluation today.

Do not fill

We connect historical research with modern accountability. Submitting this form does not immediately create an attorney-client relationship. Urgent medical issues require emergency services.

By clicking the button below, I expressly consent to be contacted by the operator of this website and one legal intake partner matched to my inquiry via phone calls, emails, and/or text messages at the number provided. I understand that this contact may include the use of an automated telephone dialing system (ATDS) or artificial/prerecorded voices. I acknowledge that my consent is not a condition of purchasing any goods or services, and I can revoke it at any time. Request Claim Assessment

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Texas?

In Texas, the statute of limitations for personal injury claims is generally two years from the date the injury is discovered or should have been discovered with reasonable diligence. For PML, the timeline between Tysabri exposure and diagnosis can be prolonged, and symptoms may initially be mistaken for multiple sclerosis relapse, which can affect when the clock starts. It is crucial to consult with an attorney promptly to preserve your rights.

What factors increase the risk of PML in Tysabri patients?

Three key factors increase the risk of PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These risk factors should be considered when initiating and continuing treatment.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Related Articles

• Virginia Tysabri Progressive Multifocal Leukoencephalopathy injury lawyer
• Massachusetts Tysabri Progressive Multifocal Leukoencephalopathy injury lawyer
• Texas Tysabri Progressive Multifocal Leukoencephalopathy injury lawyer
• Michigan Tysabri Progressive Multifocal Leukoencephalopathy injury lawyer
• Statute of limitations for Tysabri in Virginia

References

1. Tysabri Prescribing Information (DailyMed)
2. FDA Adverse Event Reporting System (FAERS) for Tysabri

Request a Free Case Review

Begin Assessment

Submitting requests an initial records screening only and does not create an attorney-client relationship.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.